Patents by Inventor Marco Tonelli

Marco Tonelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Noninvasive measurement and identification of biomarkers in disease state
    Patent number: 8026049
    Abstract: The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: September 27, 2011
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Fariba Masoumeh Assadi-Porter, Mark E. Cook, Hamid Reza Eghbalnia, Marco Tonelli, Warren Paul Porter, Daniel Elmer Butz
  • Method and system for determining compound concentrations in a mixture using regression of NMR intensity peak values
    Patent number: 7847547
    Abstract: A method of determining a concentration level of a compound in a mixture is provided. A plurality of compounds are identified in the mixture based on intensity peaks identified from NMR data generated from the mixture. A compound is selected from the identified plurality of compounds for a concentration determination. A concentration equation associated with the selected compound is determined. A first peak associated with the selected compound is selected from the NMR data. The selected first peak does not overlap with a peak associated with another compound of the identified plurality of compounds. An intensity value associated with the selected first peak is determined. A concentration of the selected compound in the mixture is calculated using the determined concentration equation and the determined intensity value.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: December 7, 2010
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: John L. Markley, Ian A. Lewis, William M. Westler, Qiu Cui, Gabriel Cornilescu, Marco Tonelli
  • METHOD AND SYSTEM FOR DETERMINING COMPOUND CONCENTRATIONS IN A MIXTURE
    Publication number: 20090192725
    Abstract: A method of determining a concentration level of a compound in a mixture is provided. A plurality of compounds are identified in the mixture based on intensity peaks identified from NMR data generated from the mixture. A compound is selected from the identified plurality of compounds for a concentration determination. A concentration equation associated with the selected compound is determined. A first peak associated with the selected compound is selected from the NMR data. The selected first peak does not overlap with a peak associated with another compound of the identified plurality of compounds. An intensity value associated with the selected first peak is determined. A concentration of the selected compound in the mixture is calculated using the determined concentration equation and the determined intensity value.
    Type: Application
    Filed: January 30, 2008
    Publication date: July 30, 2009
    Inventors: John L. Markley, Ian A. Lewis, William M. Westler, Qiu Cui, Gabriel Cornilescu, Marco Tonelli
  • Noninvasive Measurement and Identification of Biomarkers in Disease State
    Publication number: 20090104596
    Abstract: The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.
    Type: Application
    Filed: March 24, 2008
    Publication date: April 23, 2009
    Inventors: Fariba Masoumeh Assadi-Porter, Mark E. Cook, Hamid Reza Eghbalnia, Marco Tonelli, Warren Paul Porter, Daniel Elmer Butz